Amgen Inc. (AMG.DE) XETRA

242.00

+1.25(+0.52%)

Updated at September 08 09:04AM

Currency In EUR

Amgen Inc.

Address

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

United States of America

Phone

805 447 1000

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

28000

First IPO Date

January 03, 2000

Key Executives

NameTitlePayYear Born
Mr. Robert A. BradwayChairman, Chief Executive Officer & President5.75M1963
Mr. Esteban SantosExecutive Vice President of Operations2.69M1968
Mr. Peter H. GriffithExecutive Vice President & Chief Financial Officer2.69M1959
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations2.84M1967
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer2.97M1963
Dr. James E. Bradner M.D.Executive Vice President of Research & Development3.66M1972
Mr. Matthew C. BuschChief Accounting Officer & Vice President of Finance01975
Dr. Howard Y. Chang M.D., Ph.D.Senior Vice President of Global Research & Chief Scientific Officer0N/A
Justin G. ClaeysVice President of Investor Relations0N/A
Mr. Scott SkellengerSenior Vice President & Chief Information Officer0N/A

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.